Companies › Medicure
1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pyridoxal Phosphate Pyridoxal 5'-phosphate (active form of vitamin B6) cofactor replacement for PNPO deficienc | PNPO | Phase 3 | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04706013 | Pyridoxal Phosphate | Phase 3 | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | Metabolic and endocrine | Sep 2027 |
Cash of 7m CAD on 2024-12-31; operating cash flow positive
–
vTv Therapeutics Calcilytix Therapeutics, Inc., a BridgeBio company Fresenius Kabi Renibus Therapeutics Chendu DIAO Pharmaceutical Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.